BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 30470264)

  • 1. Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics.
    Synhaeve NE; van den Bent MJ; French PJ; Dinjens WNM; Atmodimedjo PN; Kros JM; Verdijk R; Dirven CMF; Dubbink HJ
    Acta Neuropathol Commun; 2018 Nov; 6(1):126. PubMed ID: 30470264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors.
    Nikiforova MN; Wald AI; Melan MA; Roy S; Zhong S; Hamilton RL; Lieberman FS; Drappatz J; Amankulor NM; Pollack IF; Nikiforov YE; Horbinski C
    Neuro Oncol; 2016 Mar; 18(3):379-87. PubMed ID: 26681766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Advances on the Molecular Pathology of Glial Neoplasms in Children and Adults.
    Rodriguez FJ; Vizcaino MA; Lin MT
    J Mol Diagn; 2016 Sep; 18(5):620-634. PubMed ID: 27444975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive DNA panel next generation sequencing approach supporting diagnostics and therapy prediction in neurooncology.
    Lorenz J; Rothhammer-Hampl T; Zoubaa S; Bumes E; Pukrop T; Kölbl O; Corbacioglu S; Schmidt NO; Proescholdt M; Hau P; Riemenschneider MJ
    Acta Neuropathol Commun; 2020 Aug; 8(1):124. PubMed ID: 32758285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
    Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
    Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraoperative Integrated Diagnostic System for Malignant Central Nervous System Tumors.
    Hayashi T; Tateishi K; Matsuyama S; Iwashita H; Miyake Y; Oshima A; Honma H; Sasame J; Takabayashi K; Sugino K; Hirata E; Udaka N; Matsushita Y; Kato I; Hayashi H; Nakamura T; Ikegaya N; Takayama Y; Sonoda M; Oka C; Sato M; Isoda M; Kato M; Uchiyama K; Tanaka T; Muramatsu T; Miyake S; Suzuki R; Takadera M; Tatezuki J; Ayabe J; Suenaga J; Matsunaga S; Miyahara K; Manaka H; Murata H; Yokoyama T; Tanaka Y; Shuto T; Ichimura K; Kato S; Yamanaka S; Cahill DP; Fujii S; Shankar GM; Yamamoto T
    Clin Cancer Res; 2024 Jan; 30(1):116-126. PubMed ID: 37851071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STING is significantly increased in high-grade glioma with high risk of recurrence.
    Zhong M; Long M; Han C; Ji S; Yang Q
    Oncoimmunology; 2024; 13(1):2327682. PubMed ID: 38516268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. System for Informatics in the Molecular Pathology Laboratory: An Open-Source End-to-End Solution for Next-Generation Sequencing Clinical Data Management.
    Kang W; Kadri S; Puranik R; Wurst MN; Patil SA; Mujacic I; Benhamed S; Niu N; Zhen CJ; Ameti B; Long BC; Galbo F; Montes D; Iracheta C; Gamboa VL; Lopez D; Yourshaw M; Lawrence CA; Aisner DL; Fitzpatrick C; McNerney ME; Wang YL; Andrade J; Volchenboum SL; Furtado LV; Ritterhouse LL; Segal JP
    J Mol Diagn; 2018 Jul; 20(4):522-532. PubMed ID: 29698836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Characterization of Advanced-Stage Melanomas in Clinical Practice Using a Laboratory-Developed Next-Generation Sequencing Panel.
    Maloberti T; De Leo A; Coluccelli S; Sanza V; Gruppioni E; Altimari A; Comito F; Melotti B; Marchese PV; Dika E; Venturi F; Corti B; Ciccimarra G; Ciceu CA; Tallini G; de Biase D
    Diagnostics (Basel); 2024 Apr; 14(8):. PubMed ID: 38667446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations to improve the clinical adoption of NGS-based cancer diagnostics in Singapore.
    Tan DS; Tan DS; Tan IBH; Yan B; Choo SP; Chng WJ; Hwang WYK
    Asia Pac J Clin Oncol; 2020 Aug; 16(4):222-231. PubMed ID: 32301274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted next-generation sequencing of 565 neuro-oncology patients at UCLA: A single-institution experience.
    Ji MS; Eldred BSC; Liu R; Pianka ST; Molaie D; Kevan B; Pan S; Lai TJ; Nguyen NT; Chow FE; Yong WH; Cox CD; Reeh DN; Li T; Liau LM; Nghiemphu PL; Cloughesy TF; Li G; Lai A
    Neurooncol Adv; 2020; 2(1):vdaa009. PubMed ID: 32118206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging Roles and Mechanisms of RNA Modifications in Neurodegenerative Diseases and Glioma.
    Kobayashi A; Kitagawa Y; Nasser A; Wakimoto H; Yamada K; Tanaka S
    Cells; 2024 Mar; 13(5):. PubMed ID: 38474421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next generation sequencing: clinical applications in solid tumours.
    Müllauer L
    Memo; 2017; 10(4):244-247. PubMed ID: 29250205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classifying glioma via liquid biopsy--progress towards an unmet clinical need.
    Abdullah KG
    Clin Cancer Res; 2024 Apr; ():. PubMed ID: 38652677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive genetic alteration profiling in primary and recurrent glioblastoma.
    Neilsen BK; Sleightholm R; McComb R; Ramkissoon SH; Ross JS; Corona RJ; Miller VA; Cooke M; Aizenberg MR
    J Neurooncol; 2019 Mar; 142(1):111-118. PubMed ID: 30535594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma.
    Indraccolo S; Lombardi G; Fassan M; Pasqualini L; Giunco S; Marcato R; Gasparini A; Candiotto C; Nalio S; Fiduccia P; Fanelli GN; Pambuku A; Della Puppa A; D'Avella D; Bonaldi L; Gardiman MP; Bertorelle R; De Rossi A; Zagonel V
    Clin Cancer Res; 2019 Mar; 25(6):1828-1837. PubMed ID: 30514778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On high-risk, low-grade glioma: What distinguishes high from low?
    Geurts M; van den Bent MJ
    Cancer; 2019 Jan; 125(2):174-176. PubMed ID: 30512190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.
    Bale TA; Jordan JT; Rapalino O; Ramamurthy N; Jessop N; DeWitt JC; Nardi V; Alvarez MM; Frosch M; Batchelor TT; Louis DN; Iafrate AJ; Cahill DP; Lennerz JK
    Neuro Oncol; 2019 May; 21(5):596-605. PubMed ID: 30496526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in managing brain metastasis.
    Kotecha R; Gondi V; Ahluwalia MS; Brastianos PK; Mehta MP
    F1000Res; 2018; 7():. PubMed ID: 30473769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Pathogenesis of Low-Grade Glioma.
    Bready D; Placantonakis DG
    Neurosurg Clin N Am; 2019 Jan; 30(1):17-25. PubMed ID: 30470401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.